CMS approves Wash. state Medicaid payment model for Hepatitis C drugs
The Centers for Medicare & Medicaid Services yesterday approved a Medicaid state plan amendment allowing Washington state to negotiate supplemental rebate agreements with drug makers based on value. CMS has approved similar state plan amendments for Oklahoma, Michigan and Colorado, but this is the first to focus on Hepatitis C drugs. Specifically, it allows the state to negotiate under a subscription model to pay a fixed annual amount to purchase an unrestricted supply of Hepatitis C drugs.
Related News Articles
Headline
The Centers for Medicare & Medicaid Services and the Food and Drug Administration April 23 announced a new pathway to expedite access to certain FDA-…
Headline
The AHA April 23 released a blog responding to a report issued April 22 by Paragon Health Institute. The blog highlights how the report relies on a long list…
Blog
In think‑tank reports, like the one released this week by Paragon Health Institute, hospitals are often reduced to abstractions — payment rates, charts,…
Headline
The Centers for Medicare & Medicaid Services announced in a memo April 21that it is delaying implementation of the Medicare Part D portion of the Better…
Headline
As published April 20, the Department of Justice released an interim final rule in the Federal Register to delay compliance dates for states and local…
Headline
The Centers for Medicare & Medicaid Services has released an updated request for applications for the Long-term Enhanced ACO Design Model, or LEAD.…